Skip to main content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Variation in use of anti-SARS-CoV-2 monoclonal antibody therapies by social vulnerability and urbanicity

Publication Date
Dec 29, 2021
Allison Kolbe

Anti-SARS-CoV-2 monoclonal antibodies are an effective treatment to prevent progression to severe COVID-19 or hospitalization in high-risk individuals. Despite the benefits offered by monoclonal antibody treatment, early reports indicated that these therapeutics were not being widely used. This brief explores variation in use of the first two monoclonal antibodies from November 2020 through March 2021, and identifies potential disparities in uptake by social vulnerability and urbanicity.

*This content is in the process of Section 508 review. If you need immediate assistance accessing this content, please submit a request to Allison Kolbe, (202) 839-1508, Content will be updated pending the outcome of the Section 508 review.

Related Content:

Product Type
ASPE Issue Brief